![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 19, 2023 11:04:23 PM
But I also call the PREACH-M trial of lenzilumab's treatment of CMML successful. Once this blazes the pathway of regulatory success for lenz, I think the FDA will recognize the futility of trying to save the covid market for Pfizer. In fact, that's already a lost cause, no matter how much lipstick the FDA puts on the mRNA vaccines. The public is not buying the hype.
But, the public will need a real covid vaccine and covid therapeutic. They will need lenz.
We just need to announce some news, and take an interim step back onto the OTC pink venue.
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM